HealthWarehouse.com Reports Results for Second Quarter 2025
HealthWarehouse.com, a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access to and reducing costs of healthcare products for consumers and business partners nationwide.
Joseph Peters, President and CEO, commented, 'Our team carried the momentum from the past nine months of rapid growth into the second quarter of 2025, resulting in continued positive financials, proving the economic scalability of our business model. We have established ourselves as a reliable service provider for high volume partners and we have shown our expertise in processing orders that require cold-chain shipping services.'
HealthWarehouse.com continues to invest in proprietary technology to remain at the forefront of new developments and offerings in the world of healthcare, focusing on patient experience, operational efficiency, and scalability.
Peters noted that the FDA has announced the end of the shortage of certain GLP1 drugs, including tirzepatide and semaglutide. That will impact pharmacies and telehealth providers like Healthwarehouse.com which have been offering compounded versions of those drugs while the principal manufacturers were unable to meet demand. Healthwarehouse.com expects to see an impact from the FDA ruling on its results for the second half of the year, starting with the third quarter.
'Fortunately, as the pharmacy world starts to focus on offerings outside of the GLP1 space, we have a robust pipeline of partner-service business, with many diversified product categories,' Peters added. 'Additionally, we are well equipped to help manufacturers launch direct-to-patient programs and are eager to develop new opportunities in that market. I am grateful for our team, as they continue to solve new problems and provide world class service to our customers.'
Overview of Results for Three and Six Months Ended June 30, 2025
Net Sales: Total net sales for the three and six months ended June 30, 2025, were $15.7 million and $30.7 million, respectively, increasing by $9.9 million (171.8%) and $19.8 million (182.0%), respectively, versus the same periods in 2024.
Prescription sales were $15.0 million and $29.4 million for the three and six months ended June 30, 2025, respectively, an increase of $10.0 million (196.5%) and $19.9 million (210.5%), respectively, compared with the same periods in 2024. The increase in prescription sales was due to growth in partner services revenue, offset by $908,000 and $1.6 million declines in the direct-to-consumer prescription business for the three- and six-months periods.
Sales of over-the-counter products were $599,000 and $1.2 million for the three and six months ended June 30, 2025, respectively, a decrease of $44,000 (6.8%) and $122,000 (9.6%), respectively, over the same periods in 2024, primarily due to a decline in Partner Services over-the-counter sales.
Gross Profit: Gross profit for the three and six months ended June 30, 2025, was $5.2 million and $9.7 million, respectively, representing increases of $2.2 million and $3.8 million, respectively, compared with the same periods in 2024. The increases were the result of higher sales offset by lower margins on our partner services prescription business. Gross margin percentages were 32.9% and 31.6% for the three and six months ended June 30, 2025, respectively, which were 18.4 and 22.7 percentage points lower, respectively, versus prior-year periods. The reduction was primarily due to lower margins in the Partner Services prescription businesses.
Operating Expenses: Selling, general and administrative expenses were $4.8 million and $9.1 million for the three and six months ended June 30, 2025, respectively, which were increases of $1.6 million (49.9%) and $2.8 million (43.3%), respectively, compared to the same periods in 2024. Expense increases included increases in shipping and shipping supplies, salaries primarily related to higher direct pharmacy labor, software engineering and business development, and advertising and legal expenses.
Net Income and Adjusted EBITDA: The Company reported net income of $228,000 and $406,000 for the three and six months ended June 30, 2025, respectively, compared with net losses of $344,000 and $596,000, respectively, for the same periods in 2024.
Earnings before interest, taxes, depreciation and amortization ('EBITDA'), as adjusted for stock-based compensation and certain non-recurring charges ('Adjusted EBITDA'), were $609,000 for the three months and $1.2 million for the six months ended June 30, 2025. That compares with Adjusted EBITDA of $25,000 and $140,000, respectively, for the three and six months ended June 30, 2024. EBITDA and Adjusted EBITDA are non-GAAP financial measures. Definitions of these non-GAAP terms and a reconciliation to GAAP measures are provided below.
Use of Non-GAAP Financial Measures
HealthWarehouse.com, Inc. (the "Company") prepares its consolidated financial statements in accordance with the United States generally accepted accounting principles ("GAAP"). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding EBITDA and Adjusted EBITDA, which are commonly used. In addition to adjusting net income or net loss to exclude interest, taxes, depreciation and amortization, including amortization of right of use lease asset, ('EBITDA'), Adjusted EBITDA also excludes stock-based compensation, and certain nonrecurring charges. EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company`s performance. Accordingly, management believes that disclosure of this metric offers lenders and other shareholders an additional view of the Company`s operations that, when coupled with GAAP results, provides a more complete understanding of the Company's financial results.
Adjusted EBITDA should not be considered as an alternative to net income, net loss or to net cash provided by or used in operating activities as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company`s performance.
About HealthWarehouse.com
HealthWarehouse.com, Inc. (OTCQB: HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy ('NABP'). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers and business partners nationwide. Based in Florence, Kentucky, the Company operates America's Leading Online Pharmacy and is a pioneer in affordable healthcare. As one of the first National Association of Boards of Pharmacy Approved Digital Pharmacies, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans. Learn more at www.HealthWarehouse.com
Forward-Looking Statements
This announcement and the information incorporated by reference herein contain 'forward-looking statements' as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward looking statements or in management's expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation and fraud. More information about factors that potentially could affect HealthWarehouse.com's financial results is included in HealthWarehouse.com's audited Annual Reports and Quarterly Reports available at otcmarkets.com and prior filings with the Securities and Exchange Commission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
What to Know TODAY: Woman Who Lost 240 Pounds Shares Question That Helped Her Eat Better
The Food and Drug Administration has issued an alert over certain cookware due to risk of lead leaching into food. Plus, a woman who dropped 240 pounds after taking up running shares her weight loss tips, and a dentist offers a simple trick to help you stop clenching your jaw. Here's what to know for Friday, Aug. 15, 2025. FDA Issues Alert Over Cookware Due to Risk of Lead Leaching Into Food Home cooks should take a close look at their pots, pans and kitchen utensils due to a risk of 'significant levels of lead' leaching into food, according to the U.S. Food and Drug Administration. The agency recently posted an alert regarding a Kada/Karahi Tiger White pure aluminum bowl because of associated health risks discovered during recent testing and shared which other products may be higher risk for leaching lead. Here's what to know. Woman Loses 240 Pounds. 1 Simple Question Helped Her Stop 'Eating Really Bad' Samantha Hager weighed nearly 380 pounds when she vowed to lose weight after visiting an amusement park with her stepsons and couldn't fit on the rides. She took up running — an activity she hated — and made changes to her diet, dropping 240 pounds in the process. Hager, 29, shares her tips for eating healthier, including the question she asked herself when she was tempted by junk food. Dentist Shares 1 Simple Breathing Exercise to Stop Clenching Your Jaw In Expert Tip of the Day, a dentist reveals how in less than a minute, you can relax your jaw muscles with this simple trick. Award-Winning Hair Tools for Combating Hair Loss, Styling Unruly Strands and More — Starting at $12 Shop TODAY's first-ever Hair Awards have landed! Staffers spent weeks curling, straightening, teasing and combing their hair to find the best tools. Consider these the best of the best. Chicken Parmesan Burgers These burgers from cookbook author Anna Francese Gass have all the flavors of a classic chicken Parm in a juicy sandwich. Since they're made on a sheet pan, cleanup is a breeze. Get the recipe! This article was originally published on
Business Insider
2 hours ago
- Business Insider
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
Tonix Pharmaceuticals (TNXP) Holding Corp. announced that the FDA approved Tonmya for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (greater than or equal to30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. Elevate Your Investing Strategy:
Business Upturn
2 hours ago
- Business Upturn
LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT
By GlobeNewswire Published on August 16, 2025, 02:30 IST LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN LEADING EDGE MATERIALS IN ANY JURISDICTION. Vancouver, August 15, 2025 – Leading Edge Materials Corp. ('Leading Edge Materials' or the 'Company') (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces announce the closing of the non-brokered private placement financing (the 'Private Placement') previously announced on June 10, 2025. Pursuant to the Private Placement, the Company has issued 17,738,500 units (the 'Units') at a price of C$0.16 per Unit for aggregate gross proceeds of C$2,838,160. Each Unit consists of one (1) common share (each, a 'Common Share') in the capital of the Company and one (1) Common Share purchase warrant (a 'Warrant'). Each Warrant will entitle the holder to purchase one Common Share (a 'Warrant Share') at a price of C$0.32 per Warrant Share until the date which is four (4) years from the closing date of the Private Placement (the 'Closing Date'). Leading Edge Materials intends to use net proceeds for the Company's projects, located in Sweden and Romania and for general working capital and corporate purposes. A finder's fee of 6% was paid to arm's length third party on a portion of the Private Placement. The Private Placement is subject to final approval from the TSX Venture Exchange (the 'Exchange'). The securities issued pursuant to the Private Placement are subject to applicable statutory resale restrictions, including a hold period expiring on December 15, 2025, pursuant to applicable Canadian securities laws. Insiders of the Company purchased a total of 10,666,000 Units under the Private Placement which constitutes a 'related party transaction' as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 based on the fact that neither the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company's market capitalization as determined in accordance with MI 61-101. Mr. Eric Krafft, a director of the Company, has subscribed for and acquired 10,666,000 Common Shares under the Private Placement. Prior to the Private Placement, Mr. Krafft beneficially owned and controlled 85,056,577 Common Shares and 22,852,173 warrants of the Company. Mr. Krafft is a Control Person (as defined by the policies of the Exchange), beneficially holding 95,722,577 common shares and 33,518,173 warrants of the Company, representing approximately 38.30% of the issued and outstanding Common Shares on a non-diluted basis, and 48.28% on a partially diluted basis, assuming the exercise of warrants held by Mr. Krafft only. The Company obtained disinterested shareholder approval at the Annual General Meeting held on July 24, 2020 for Mr. Krafft to become a Control Person of the Company. Eric Krafft has acquired the Units for investment purposes and has a long-term view of his investment. In the future, Mr. Krafft may take such actions in respect of his investment in the Company as he may deem appropriate, depending on the market conditions and circumstances at that time. The foregoing disclosure regarding Mr. Krafft's holdings is being disseminated pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (NI 62-103). A copy of Mr. Krafft's early warning report will appear on the Company's profile on SEDAR Plus. The information herein with respect to the number of Mr. Krafft's securities and his intention relating thereto are not within the knowledge of the Company and are provided by Mr. Krafft. The securities have not been, and will not be, registered under the U.S. Securities Act, or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is not a prospectus under Regulation (EU) 2017/1129 (the 'EU Prospectus Regulation'). The Company has not authorized any offer of securities to the public (as defined in the EU Prospectus Regulation) in any EEA member state and no such prospectus has been or will be prepared in connection with the Private Placement. On behalf of the Board of Directors, Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at: [email protected] Follow usTwitter: Linkedin: About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden) and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information This information is information that Leading Edge Materials Corp. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at August 15, 2025 at 2:30 PM Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol 'LEM', OTCQB under the symbol 'LEMIF' and Nasdaq First North Stockholm under the symbol 'LEMSE'. Svensk Kapitalmarknadsgranskning ('SKMG') is the Company's Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email [email protected] or by phone +46 (0)8 913 008. Reader Advisory This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including statements with respect to the closing of the Private Placement, the receipt of regulatory approvals, and the use of proceeds from the Private Placement. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, the Company's ability to close the Private Placement, the Company's ability to obtain the required regulatory approvals, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Important information for EEA Investors The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. Any investment decision in connection with the Private Placement must be made on the basis of all publicly available information relating to the Company and the Company's shares/Units. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares/Units. This press release is not a prospectus for the purposes of the EU Prospectus Regulation. Leading Edge Materials has not authorized any offer to the public of Units, shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, 'qualified investors' who are (i) persons having professional experience in matters relating to investments who fall within the definition of 'investment professionals' in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Attachment LEM – 2025 News Release Annoucing Closing of Financing-final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
